Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Ascendis Pharma (ASND) Stock Price & Analysis
393 Followers
ASND Stock Chart & Stats
Day’s Range$136 - $140.84
52-Week Range― - ―
Previous Close$138.44
Volume90.69K
Average Volume (3M)N/A
Market Cap
$7.84B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$190.63Price Target Upside35.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Ascendis Pharma News
PremiumCompany Announcements
Ascendis Pharma A/S Boasts Strong Q1 Growth
PremiumCompany Announcements
Ascendis Pharma Posts Q1 Revenue Growth Amid Losses
PremiumCompany Announcements
Ascendis Pharma Outlines AGM Agenda and Proposals
PremiumCompany Announcements
Ascendis Pharma Gains UK Authorization for YORVIPATH
Bulls Say, Bears Say
Bulls Say
Competitive PositioningThe clinical profile of eneboparatide shows limited differentiation from Ascendis Pharma's TransCon PTH, suggesting strong competitive positioning for the latter.
Market AccessPayer discussions suggest that TransCon PTH will have good market access, with unique circumstances favoring its adoption.
Market OpportunityAmolyt acquisition highlights the attractiveness of the hypoparathyroidism market, providing large pharma validation of the opportunity that Ascendis Pharma's TransCon PTH is targeting.
Bears Say
Market CompetitionIn the competitive landscape for achondroplasia treatments, TransCon CNP faces strong competitors, which could impact its market position.
Sales ProjectionsGiven the competition, sales projections for the product are conservative with an estimated $72M at peak.
Supply IssuesDaily GH shortages have continued to provide tailwinds, though supply constraints of market leader Norditropin are expected to resolve.
---
Ownership Overview
0.00%
Insiders
41.25% Mutual Funds
1.71% Other Institutional Investors
57.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Currently, no data Available
What is Ascendis Pharma’s market cap?
Currently, no data Available
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is May 02, 2024 which is 4 days ago.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Feb 07, 2024. The company reported -$1.642 earnings per share for the quarter, beating the consensus estimate of -$1.923 by $0.281.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -$1.57.
How many shares outstanding does Ascendis Pharma have?
Currently, no data Available
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$1.642 in its last earnings report, beating expectations of -$1.923. Following the earnings report the stock price went down -0.029%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Among the largest hedge funds holding Ascendis Pharma’s share is RA Capital Management. It holds Ascendis Pharma’s shares valued at 1B.
---
Ascendis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$190.63 (35.05% Upside)
$190.63 (35.05% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 463.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.88%
12-Months-Change
Fundamentals
Return on Equity
-867.62%
Trailing 12-Months
Asset Growth
-21.58%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
---
ASND Earnings Call
Q4 2024
0:00 / 0:00
---
ASND Stock 12 Months Forecast
Average Price Target
$190.63
▲(35.05% Upside)
Technical Analysis
Best Analysts Covering ASND
1 Year
1 Year Success Rate
17/20 ratings generated profit
1 Year Average Return
+34.71%
reiterated a buy rating 24 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +34.71% per trade.
---